Advertisement

The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy

  • Dan Călugăru
  • Mihai Călugăru
Letter to the Editor
  • 117 Downloads

Dear Editor:

We would like to address several challenges that have arisen from the study by Garweg et al. [1] which can be specifically summarized below.

The first inclusion criterion for the patients in this series was the presence of choroidal neovascularization (CNV) confirmed angiographically, in the context of wet age-related macular degeneration (wAMD) requiring intravitreal therapy, as indicated by the loss of best-corrected visual acuity (BCVA) and the manifestation of intraretinal and subretinal fluid in optical coherence tomography. The wAMD patients were not investigated with regard to the possible presence of the following six angiographic subtypes of CNV, namely, the occult, minimally classic, predominantly classic, mixed CNV, the retinal angiomatous proliferation, and the polypoidal choroidal vasculopathy. The treatment would have had to be individualized according to the existing angiographic subtype [2]. Indocyanine green angiography should be a standard investigation...

Notes

Author contribution

Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Garweg JG, Zirpel JJ, Gerhardt C, Pfister IB (2018) The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. Graefes Arch Clin Exp Ophthalmol 256:823–831CrossRefPubMedGoogle Scholar
  2. 2.
    Călugăru D, Călugăru M (2018) Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 256:233–235CrossRefPubMedGoogle Scholar
  3. 3.
    Grover SG, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRefPubMedGoogle Scholar
  4. 4.
    Călugăru D, Călugăru M (2017) Long-term remission of neovascular age-related macular degeneration with as-needed anti-vascular endothelial growth factor therapy. Retina 37:108–110CrossRefGoogle Scholar
  5. 5.
    Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration. Am J Ophthalmol 173:145–146CrossRefPubMedGoogle Scholar
  6. 6.
    Jaffe GJ, Kaiser PK, Thompson D et al (2016) Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology 123:1856–1864CrossRefPubMedGoogle Scholar
  7. 7.
    Călugăru D, Călugăru M (2017) High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 255:2067–2068CrossRefPubMedGoogle Scholar
  8. 8.
    Călugăru D, Călugăru M (2018) Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 256:627–629CrossRefPubMedGoogle Scholar
  9. 9.
    Călugăru D, Călugăru M (2017) Intravitreal dexamethasone implant as adjuvant treatment for bevacizumab- and ranibizumab-resistant neovascular age-related macular degeneration. Retina 37:78–79CrossRefGoogle Scholar
  10. 10.
    Călugăru D, Călugăru M (2017) Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol 174:185–186CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-Napoca/RomaniaCluj-NapocaRomania

Personalised recommendations